Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

Table 4 Number of patients with deteriorating BILAG activities from baseline

BILAG body system (N = 14)^a	6 weeks^b	10 weeks	18 weeks
General	0 (0 %)	0 (0 %)	0 (0 %)
Mucocutaneous	0 (0 %)	0 (0 %)	0 (0 %)
Neurological	0 (0 %)	0 (0 %)	0 (0 %)
Musculoskeletal	0 (0 %)	0 (0 %)	0 (0 %)
CV/Respiratory	0 (0 %)	0 (0 %)	1 (7 %)
Vasculitis	0 (0 %)	0 (0 %)	0 (0 %)
Renal	0 (0 %)	1 (7 %)	0 (0 %)
Hematology	1 (7 %)	1 (7 %)	2 (14%)
Overall^c	1 (7 %)	2 (14%)	3 (21%)

^aN = total number of patients. ^bTwenty-four hours after fourth infusion. ^cAs applied to any BILAG body system.

ISSN: 1478-6362